血清endocan水平与心血管疾病关联性的Meta分析

发布时间：2019-08-20 13:54

【摘要】：目的:评价血清endocan与心血管疾病(CVD)的关联性。方法:计算机检索Pubmed、Embase、Web of Science、中国知网(CNKI)、万方、维普、中国生物医学文献服务系统(SinoMed),检索自建库以来至2017年3月1日发布的国内外相关文献,提取数据后,采用Stata 12软件进行Meta分析。结果:共13篇研究符合纳入标准,累计病例数1 356例,对照组946例。Meta分析结果表明,高血压、冠心病、冠状动脉(冠脉)血流缓慢患者血清Endocan水平较对照组升高,其合并标准化均数差值及其95%CI分别为0.69(0.30~1.09)、0.99(0.51~1.39)、0.62(0.45~0.78)(均P0.01)。进一步分析,高血压发生冠心病的患者血清endocan水平高于单纯高血压患者[0.61(0.30~0.92),P0.01]。结论:血清endocan水平可能是CVD发病的危险因素,但其病因关联性仍需随机对照试验研究进一步验证。
[Abstract]:Objective: to evaluate the relationship between serum endocan and cardiovascular disease (CVD). Methods: the Pubmed,Embase,Web of Science, China knowledge Network (CNKI), Wanfang, Vipp and China Biomedical Literature Service system (SinoMed), were searched by computer to retrieve the relevant literature published from the establishment of the database to March 1, 2017. After extracting the data, Meta analysis was carried out with Stata 12 software. Results: a total of 13 studies met the inclusion criteria, with a cumulative number of 1556 cases and a control group of 946 cases. Meta-analysis showed that the serum Endocan levels in patients with hypertension, coronary heart disease and slow coronary artery flow were higher than those in the control group, and the standardized mean difference and 95%CI were 0.69 (0.30 鈮，

本文编号：2528674